vasotocin has been researched along with Astrocytoma, Grade IV in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Areces, L; Bussolati, G; Cassoni, P; Chini, B; Chinol, M; Manning, M; Marrocco, T; Paganelli, G; Papi, S; Reversi, A | 1 |
| Bussolati, G; Cassoni, P; Chini, B; Chinol, M; Nacca, A; Paganelli, G | 1 |
2 other study(ies) available for vasotocin and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue.
Topics: Animals; Breast Neoplasms; Carcinoma; Chelating Agents; COS Cells; Glioblastoma; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Isotope Labeling; Mice; Neoplasms; Oxytocin; Protein Binding; Radioactive Tracers; Radioligand Assay; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Oxytocin; Sensitivity and Specificity; Stomach Neoplasms; Tissue Distribution; Transfection; Tumor Cells, Cultured; Vasotocin | 2003 |
111In-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors.
Topics: Animals; Breast Neoplasms; COS Cells; Female; Glioblastoma; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HT29 Cells; Humans; Indium Radioisotopes; Isotope Labeling; Kinetics; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Radiopharmaceuticals; Receptors, Oxytocin; Tissue Distribution; Vasotocin | 2001 |